Compare Cytokinetics Inc (CYTK) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Palo Alto Networks Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Palo Alto Networks Inc trades at $403.2 (market cap $331.76B). The key difference: Palo Alto Networks Inc is far larger — about 38.5× Cytokinetics Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Palo Alto Networks Inc for 82 Days on average.
| CYTK | PANW | |
|---|---|---|
Market Cap | $8.62B | $331.76B |
Volume | 2,594,626 | 3,886,927 |
Sector | Health | Technology |
52-Week High | $87.26 | $419.91 |
52-Week Low | $54.76 | $141.67 |
Typical Hold Time | 19 Days | 82 Days |
Enterprise Value | $8.72B | $331.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Palo Alto Networks (PANW) trades at $405.41, down 3.45% today but remains near recent highs, supported by strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth is robust, climbing from $5.5B in 2022 to $9.2B in 2025, though net margins have fluctuated. Positive sentiment is driven by AI-driven cybersecurity demand and platformization strategy gains.
Outlook: PANW offers growth exposure to the expanding cybersecurity market, with AI integration as a key catalyst. Risks include premium valuation multiples, rising costs, and competitive pressures. Analyst consensus is strongly bullish with a $398.70 price target, but investors should weigh high P/S and EV/EBITDA ratios against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
